These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 12661474)
1. Antidepressant response and fluvoxamine plasma concentrations: a pilot study. Schwarzenbach F; Netillard C; Demoly P; Bisschop D; Limat S; Bouquet S; Vandel S; Bel AM; Woronoff-Lemsi MC Pharm World Sci; 2003 Feb; 25(1):27-9. PubMed ID: 12661474 [TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C Pharmacopsychiatry; 1998 Sep; 31(5):199-200. PubMed ID: 9832352 [TBL] [Abstract][Full Text] [Related]
3. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C Ther Drug Monit; 1998 Aug; 20(4):446-9. PubMed ID: 9712472 [TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. Claghorn JL; Earl CQ; Walczak DD; Stoner KA; Wong LF; Kanter D; Houser VP J Clin Psychopharmacol; 1996 Apr; 16(2):113-20. PubMed ID: 8690826 [TBL] [Abstract][Full Text] [Related]
5. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. van den Broek WW; Birkenhäger TK; Mulder PG; Bruijn JA; Moleman P Psychopharmacology (Berl); 2004 Oct; 175(4):481-6. PubMed ID: 15243735 [TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Kasper S; Dötsch M; Kick H; Vieira A; Möller HJ Eur Neuropsychopharmacol; 1993 Mar; 3(1):13-21. PubMed ID: 8471827 [TBL] [Abstract][Full Text] [Related]
7. Interaction between fluvoxamine and cotinine or caffeine. Yoshimura R; Ueda N; Nakamura J; Eto S; Matsushita M Neuropsychobiology; 2002; 45(1):32-5. PubMed ID: 11803239 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. DeVane CL; Ware MR; Emmanuel NP; Brawman-Mintzer O; Morton WA; Villarreal G; Lydiard RB Int Clin Psychopharmacol; 1999 Nov; 14(6):345-51. PubMed ID: 10565801 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa. Ikenouchi-Sugita A; Yoshimura R; Hori H; Ueda N; Nakamura J Psychiatry Clin Neurosci; 2007 Aug; 61(4):452. PubMed ID: 17610677 [No Abstract] [Full Text] [Related]
10. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Hewer W; Rost W; Gattaz WF Eur Arch Psychiatry Clin Neurosci; 1995; 246(1):1-6. PubMed ID: 8773212 [TBL] [Abstract][Full Text] [Related]
11. An open-label pilot study of fluvoxamine for mixed anxiety-depression. Houck C Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001 [TBL] [Abstract][Full Text] [Related]
13. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708 [TBL] [Abstract][Full Text] [Related]
14. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Grassi B; Gambini O; Scarone S Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371 [TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Terra JL; Montgomery SA Int Clin Psychopharmacol; 1998 Mar; 13(2):55-62. PubMed ID: 9669185 [TBL] [Abstract][Full Text] [Related]
16. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients. Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590 [TBL] [Abstract][Full Text] [Related]
17. EPMS under antidepressive therapy with fluvoxamine and concomitant antibiotic therapy with clindamycin. Jakob F; Wolf J Pharmacopsychiatry; 2007 May; 40(3):129. PubMed ID: 17541891 [No Abstract] [Full Text] [Related]
18. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Benedetti F; Dallaspezia S; Colombo C; Lorenzi C; Pirovano A; Smeraldi E Eur Psychiatry; 2010 Dec; 25(8):476-8. PubMed ID: 20619611 [TBL] [Abstract][Full Text] [Related]
19. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690 [TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. Franchini L; Zanardi R; Gasperini M; Perez J; Smeraldi E J Affect Disord; 1996 Apr; 38(1):67-9. PubMed ID: 8735160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]